Key Takeaways Pfizer said it will discontinue development of oral daily weight-loss treatment danuglipron.A Phase 3 trial participant experienced a "liver injury" while taking the drug that "resolved" ...

UF scientists have developed a compound that safely activates delta opioid receptors, offering pain relief without ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.